Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 19;15(1):52.
doi: 10.1186/s12969-017-0180-2.

Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis

Sonja Falvey  1 , Lauren Shipman  2 , Norman Ilowite  3 , Timothy Beukelman  4
Affiliations
Review

Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis

Sonja Falvey et al. Pediatr Rheumatol Online J. .

Abstract

Background: Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients.

Main body: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach.

Conclusion: Understanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.

Keywords: JIA; Juvenile idiopathic arthritis; MTX; Methotrexate; Nausea; Vomiting.

PubMed Disclaimer

References

    1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392. - PubMed
    1. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2012;59(2):301–327. doi: 10.1016/j.pcl.2012.03.014. - DOI - PubMed
    1. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric rheumatology collaborative study group and the cooperative Children's study group. N Engl J Med. 1992;326(16):1043–1049. doi: 10.1056/NEJM199204163261602. - DOI - PubMed
    1. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–1857. doi: 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F. - DOI - PubMed
    1. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate registry. Arthritis Care Res (Hoboken) 2012;64(9):1349–1356. doi: 10.1002/acr.21697. - DOI - PubMed

MeSH terms